ALIFBS Stock Overview
AddLife AB (publ), together with its subsidiaries, provides equipment, consumables, and reagents primarily to healthcare sector, research, colleges, and universities, as well as the food and pharmaceutical industries.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
AddLife AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr65.25 |
| 52 Week High | kr140.00 |
| 52 Week Low | kr65.25 |
| Beta | 1.19 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -39.67% |
| 3 Year Change | -54.62% |
| 5 Year Change | 15.74% |
| Change since IPO | 67.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALIFBS | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 0% | 7.4% | 1.0% |
| 1Y | -39.7% | -42.0% | 3.0% |
Return vs Industry: ALIFBS underperformed the UK Life Sciences industry which returned -12.1% over the past year.
Return vs Market: ALIFBS underperformed the UK Market which returned -1.1% over the past year.
Price Volatility
| ALIFBS volatility | |
|---|---|
| ALIFBS Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 5.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: ALIFBS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ALIFBS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1906 | 2,314 | Fredrik Dalborg | www.add.life |
AddLife AB (publ), together with its subsidiaries, provides equipment, consumables, and reagents primarily to healthcare sector, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory equipment for haematology, pathology, point-of-care diagnostics, cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, consumables, and analytical instruments segments.
AddLife AB (publ) Fundamentals Summary
| ALIFBS fundamental statistics | |
|---|---|
| Market cap | kr13.33b |
| Earnings (TTM) | kr292.00m |
| Revenue (TTM) | kr9.47b |
45.7x
P/E Ratio1.4x
P/S RatioIs ALIFBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALIFBS income statement (TTM) | |
|---|---|
| Revenue | kr9.47b |
| Cost of Revenue | kr5.92b |
| Gross Profit | kr3.54b |
| Other Expenses | kr3.25b |
| Earnings | kr292.00m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 02, 2024
| Earnings per share (EPS) | 2.40 |
| Gross Margin | 37.44% |
| Net Profit Margin | 3.08% |
| Debt/Equity Ratio | 102.1% |
How did ALIFBS perform over the long term?
See historical performance and comparison